Project description:JMJD1C shows ubiquitous expression and is often downregulated in tumor entities compared to healthy tissues.JMJD1C inhibit growth of the glioblastoma cell line LN-229. Here, JMJD1C knockdown leads to malignant progression in the glioblastoma cell line LN-229.
Project description:We performed RNA-seq to determine the impact of MOB2 depletion on global gene expression profile.The results reveal that dysregulated genes were enriched for genes related to pathways in cancer, including PI3K–AKT signaling, cell adhesion molecules (CAMs), focal adhesion and cytokine-cytokine interaction.
Project description:To investigate whether IDH1 mutation influence the effects of oncolytic virus VSVΔ51, we transduced doxycycline-inducible IDH1-R132H lentiviruses into LN-229 to establish the LN-229-TRE-R132H cell line. We then performed gene expression profiling analysis using data obtained from RNA-seq of LN-229-TRE-R132H cells infected with or without VSVΔ51 in the presence or absence of IDH1 mutation induced by doxycycline.
Project description:Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature it cannot be completely removed. We have recently shown that the WNT inhibitory factor 1 (WIF1), a secreted inhibitor of WNTs, is downregulated in glioblastoma and acts as strong tumor suppressor. In search of a mediator for this function differential gene expression profiles of WIF1-expressing cells were performed. MALAT1, a long non-coding RNA and key positive regulator of invasion, emerged as the top downregulated gene. Indeed, knock-down of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. LN-229 cells induced with Doxocyclin to express WIF1 were compared to the non-induced control (two biological replicates each)
Project description:RUNX1-ETO knockdown was performed in Kasumi-1 cells and transcriptomic analyses by RNA-sequencing were performed at two different time points (day2 and day9). Control cells (Kasumi-1 shControl) were also analysed at day2 and day9. All samples were analysed in triplicates.
Project description:RUNX1-ETO knockdown was performed in Kasumi-1 cells and Pro-seq analyses were performed. Control cells (Kasumi-1 shControl) were also analysed and all samples were analysed in duplicates.